Moon­Lake's PhII da­ta on skin dis­ease set it up against Cosen­tyx, UCB and oth­ers in IL-17 field

Moon­Lake Im­munother­a­peu­tics says it’s cleared the bar in a Phase II tri­al of its IL-17A and IL-17F in­hibitor in hidradeni­tis sup­pu­ra­ti­va.

In its 234-pa­tient MI­RA study, Moon­Lake said it suc­ceed­ed on the pri­ma­ry goal — more pa­tients on its in­ves­ti­ga­tion­al med sonelokimab achieved at least a 75% re­duc­tion from base­line in to­tal ab­scess and in­flam­ma­to­ry nod­ule count than those on place­bo. Peo­ple with HS ex­pe­ri­ence re­cur­ring nod­ules and ab­scess­es in the armpits, groin and but­tocks, and si­nus tracts. It leads to pain and some­times stigma­ti­za­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.